We're taking a closer look at Summit Therapeutics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved -4.3% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
-
Summit Therapeutics has moved -5.0% over the last year compared to 14.3% for the S&P 500 -- a difference of -19.3%
-
SMMT has an average analyst rating of buy and is -45.91% away from its mean target price of $31.89 per share
-
Its trailing 12 month earnings per share (EPS) is $-1.25
-
Summit Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -13.8 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $-0.38 and its forward P/E ratio is -45.4
-
The company has a Price to Book (P/B) ratio of 66.86 in contrast to the S&P 500's average ratio of 4.74
-
Summit Therapeutics is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
-
Summit Therapeutics has on average reported free cash flows of $-69671166.7 over the last four years, during which time they have grown by an an average of -32.2%
